

- **Name:** Damon Hostin
 - **Current Position & Affiliation:** Lead, Health System Market Access, Illumina
 - **Country:** USA
-

• **Educational Background:** BS, Tulane University, Masters studies at Harvard, and certificate programs at The Wharton School of the University of Pennsylvania and the US National Institutes of Health.

• **Professional Experience:**

- Lead for Health Systems in Illumina's Market Access department.
- Multiple leadership positions at Catholic Health Initiatives (CHI), culminating in leading the Precision Medicine Alliance of CHI and Dignity Health - the forming systems of CommonSpirit Health.
- Clinical business leader for Complete Genomics
- Lead the Life Science segment of SDIX (now Origene) antibody and clinical assay business, including IVD production, research tools and therapeutic candidate generation.
- General manager of GenVis Labs, a clinical molecular diagnostic company purchased by Pfizer in 2005.
- Founding Team of Actinium Pharmaceuticals, managing alliances in developing targeted oncology therapeutics.
- His start in genomics was as Team Leader, Sequencing at Celera Genomics.

• **Professional Organizations:**

• **Main Scientific Publications:**

- *The Sequence of the Human Genome*, Science. 2001 Feb 16; 291 (5507): 1304-1351.
- *The Genome Sequence of Drosophila Melanogaster*, Science. 2000 Mar 24; 287 (5461): 2185-95.
- *Sequence-Based Antibody Development*, Innovations in Pharmaceutical Technology. 2008 May 5; 55-57.
- *Genetic Immunization in the Development of Antibody Therapeutics*, Innovations in Pharmaceutical Technology. 2008 April 12th; 62-65.
- *Proteomic Tools for the Study of Model Organisms*, International Pharmaceutical Industry. 2009 Summer; 28-31.
- *Survey of Tissue Specimen Collection Techniques: Impact on Biomarker Data Quality*, NCI Biorepository Forum, 2011
- *Genome Based Therapeutics*, National Academy of Science, 2012